Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 234 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: epoetin Clear all
Recruiting Phase 2 Interventional

Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

NCT05340465
View directory record Official record
Conditions
Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
Interventions
Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection, Oral iron supplements
Drug
Lead sponsor
University of Washington
Other
Eligibility
Up to 3 Days
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

NCT01628107
View directory record Official record
Conditions
Chronic Renal Failure Requiring Hemodialysis
Interventions
Epoetin Hospira
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
108
States / cities
Azusa, California • Bellflower, California • Commerce, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 20, 2026, 11:21 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

NCT03140722
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
vadadustat, epoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Bakersfield, California • Elk Grove, California • Encino, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 20, 2026, 11:21 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

NCT07422480
View directory record Official record
Conditions
Myelodysplastic Syndrome, Anemia
Interventions
Elritercept, Epoetin Alfa
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
31
States / cities
Gilbert, Arizona • Duarte, California • Santa Rosa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Early Phase 1 Interventional

Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease

NCT03842254
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
Erythropoietin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 74 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Oct 20, 2026, 11:21 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

NCT04798339
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Canakinumab Injection, Darbepoetin Alfa
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 20, 2026, 11:21 AM EDT
Withdrawn Phase 2 Interventional

Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations

NCT00624312
View directory record Official record
Conditions
Cancer
Interventions
Procrit, Placebo
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 2 Interventional Results available

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

NCT03552393
View directory record Official record
Conditions
Anemia, Renal Insufficiency, Chronic
Interventions
Mircera
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Months to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
7
States / cities
Birmingham, Alabama • Loma Linda, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 20, 2026, 11:21 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

NCT00454246
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2011 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Results available

PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients

NCT00440466
View directory record Official record
Conditions
Anemia, Renal Diseases
Interventions
epoetin alfa
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
66
States / cities
Chula Vista, California • Fountain Valley, California • Los Angeles, California + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)

NCT01913340
View directory record Official record
Conditions
Hypoxic-ischemic Encephalopathy, Neonatal Encephalopathy, Birth Asphyxia
Interventions
Erythropoietin, Normal saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Minutes to 24 Hours
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Little Rock, Arkansas • Palo Alto, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

NCT02876835
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, Darbepoetin alfa, Placebo, Iron Therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
3,872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
161
States / cities
Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 20, 2026, 11:21 AM EDT
Terminated Phase 4 Interventional

Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

NCT00223938
View directory record Official record
Conditions
Anemia
Interventions
Oral Iron, sodium ferric gluconate
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
8
States / cities
Hot Springs, Arkansas • Orange County, California • Simi Valley, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 20, 2026, 11:21 AM EDT
Terminated Phase 2 Interventional Results available

Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa

NCT00210626
View directory record Official record
Conditions
Anemia
Interventions
PROCRIT, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • Santa Barbara, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 20, 2026, 11:21 AM EDT
Terminated Phase 2 Interventional Results available

Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD

NCT00372489
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
9
States / cities
Pine Bluff, Arkansas • Mountain View, California • Lauderdale Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2012 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

NCT02504294
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
Epoetin Hospira Arm, Standard of Care Arm, IV Iron
Biological · Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
42
States / cities
Chula Vista, California • Poway, California • Rancho Bernardo, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 20, 2026, 11:21 AM EDT
Completed No phase listed Observational

Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease

NCT01719146
View directory record Official record
Conditions
Anemia of End Stage Renal Disease
Interventions
Specimen collection
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
3
States / cities
Louisville, Kentucky • Springfield, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 2 Interventional Results available

Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)

NCT00286182
View directory record Official record
Conditions
Anemia
Interventions
Erythropoietin alpha, Placebo
Drug
Lead sponsor
Mathew S. Maurer
Other
Eligibility
55 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 2 Interventional Results available

Darbepoetin Administration to Preterm Infants

NCT00334737
View directory record Official record
Conditions
Infant, Newborn
Interventions
Darbepoetin Alfa Injection, erythropoietin alfa injection, sham injection
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
1 Hour to 49 Hours
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
3
States / cities
Denver, Colorado • Ogden, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Results available

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

NCT00338286
View directory record Official record
Conditions
Breast Cancer, Neoplasm Metastasis
Interventions
Standard supportive care (packed RBC transfusion), epoetin alfa + packed RBC transfusion
Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
2,098 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
14
States / cities
Anaheim, California • Gainesville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease

NCT00440557
View directory record Official record
Conditions
Anemia
Interventions
Epoetin alfa 3 times weekly /once weekly, Epoetin alfa once weekly, Epoetin alfa once every two weeks
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
61
States / cities
Glendale, Arizona • Tempe, Arizona • Chula Vista, California + 58 more
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 20, 2026, 11:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Erythropoietin in Myelodysplastic Syndrome

NCT00723112
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 23, 2010 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Results available

Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis

NCT01478971
View directory record Official record
Conditions
Chronic Kidney Disease, Anemia
Interventions
Epoetin, Peginesatide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Sacramento, California • San Diego, California • San Jose, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 20, 2026, 11:21 AM EDT
Completed Phase 2 Interventional Results available

Optimized Erythropoietin (EPO) Treatment

NCT02075970
View directory record Official record
Conditions
Neonatal Anemia
Interventions
Epoetin Alpha
Drug
Lead sponsor
University of Iowa
Other
Eligibility
Up to 2 Days
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 20, 2026, 11:21 AM EDT